Clinical Trial Update: Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant apalutamide with radical prostatectomy for intermediate to high-risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: Singapore General Hospital | Conditions: Cancer of the Prostate | Phase 2 | Status: COMPLETED